Home›Trial›NCT07219121
NCT07219121Phase 4RECRUITING

Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis

Study Summary

To evaluate the safety and efficacy of sparsentan tablets for the treatment of patients with proteinuria after kidney transplantation with once-daily dosing for 36 weeks.

Conditions
ProteinuriaImmunoglobulin A (IgA) NephropathyFocal Segmental GlomerulosclerosisKidney Transplant
Interventions / Drugs
Sparsentan
View on ClinicalTrials.gov ↗
Sponsor
TVTX
Travere Therapeutics
Nephrology
C61/100
Study Details
Enrollment20 participants
Primary Completion—
Lead SponsorTravere Therapeutics, Inc.
Data Retrieved2026-04-11 04:30:13.942951+00:00
What This Trial Means for Biotech Investors
Trial Phase Context

This trial phase represents an early or specialized stage of clinical development.

Status & Expected Data

Currently recruiting: the trial is enrolling patients. A data readout is not expected until after enrollment closes and the follow-up period is complete.

Enrolled: 20 participants
Sponsor Catalyst Profile

Travere Therapeutics (TVTX) is the sponsoring company for this trial. BiotechSign currently grades this company C (61/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

TVTX Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.